Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease

Expert Opinion on Investigational Drugs
Leon P McLean, Raymond K Cross

Abstract

Anti-integrin therapy for the treatment of patients with Crohn's disease is rapidly evolving. Two agents, natalizumab and vedolizumab, are approved by the United States Food and Drug Administration for the treatment of Crohn's disease, with vedolizumab the primary anti-integrin used due to a more favorable safety profile. Several other anti-integrins are in various stages of development. This review discusses the current state of anti-integrin therapy as well as suggestions for positioning of these agents in clinical practice. Emerging anti-integrin therapies, their underlying mechanisms of action, and available safety and clinical data are also reviewed. Anti-integrins are effective for the treatment of Crohn's disease, even in patients refractory to other therapies. Their use should be considered in patients with Crohn's disease who do not respond to, develop non-response to, or have contraindications to anti-TNF therapy. Anti-integrin therapies can be offered as a first biologic therapy, in particular for older patients, patients with concurrent multiple sclerosis (natalizumab only), and in patients with contraindications to anti-TNF therapy. In patients with more severe symptoms, providers should consider co-induction with ...Continue Reading

References

May 1, 1994·Gut·J SatsangiJ I Bell
Dec 21, 2000·The British Journal of Surgery·O BernellG Hellers
Jan 1, 2005·Inflammatory Bowel Diseases·Tanja Birrenbach, Ulrich Böcker
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Feb 14, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Bruce YacyshynEmil Chuang
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Jul 27, 2007·Nature·R J Xavier, D K Podolsky
Jul 10, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Yvette Leung, Remo Panaccione
Jul 3, 2010·Expert Review of Clinical Immunology·Gionata FiorinoSilvio Danese
Sep 18, 2010·Inflammatory Bowel Diseases·Dawn R EbachChris S Jensen
Oct 5, 2010·Journal of Digestive Diseases·Anja Schirbel, Claudio Fiocchi
Mar 4, 2011·Alimentary Pharmacology & Therapeutics·S Ben-Horin, Y Chowers
Oct 11, 2012·Immunotherapy·Leon P McLeanRaymond K Cross
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Dec 11, 2013·Cellular Immunology·Sean BandzarManu O Platt
Aug 11, 2015·Gastroenterology·Dermot McGovernJudy H Cho
Aug 20, 2015·Inflammatory Bowel Diseases·Edward SheltonVijay Yajnik

❮ Previous
Next ❯

Citations

Apr 21, 2016·Expert Opinion on Drug Metabolism & Toxicology·Leon P McLean, Raymond K Cross
Aug 24, 2017·Expert Opinion on Biological Therapy·Cristiano PagniniFabio Cominelli
Jul 10, 2018·Expert Opinion on Investigational Drugs·Mariangela AlloccaSilvio Danese
Oct 30, 2018·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Shoichi IidaRobert L Fairchild
Jul 12, 2019·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Sunao TanakaJunji Itou
Jul 13, 2017·Clinical Pharmacology and Therapeutics·Pieter HindryckxSilvio Danese
Jan 20, 2018·European Journal of Gastroenterology & Hepatology·Mariangela AlloccaSilvio Danese
Mar 15, 2018·Cells·Menghon Cheah, Melissa R Andrews
Mar 9, 2021·Frontiers in Immunology·Panagiota BoutiTaco W Kuijpers
Oct 10, 2020·Drug Discovery Today·Danielle NaderSteven W Kerrigan
Jun 4, 2021·Journal of Asthma and Allergy·Brennan J BlightAbigail Pulsipher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Related Papers

Current Gastroenterology Reports
Parakkal Deepak, D H Bruining
Expert Opinion on Biological Therapy
Neal ShahidiRemo Panaccione
Gastroenterology Report
Zubin Arora, Bo Shen
Gastroenterology & Hepatology
Gary LichtensteinW J Sandborn
© 2021 Meta ULC. All rights reserved